Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Radiotherapy is one of the most successful cancer therapies. Here the effect of irradiation on antigen presentation by MHC class I molecules was studied. Cell surface expression of MHC class I molecules was increased for many days in a radiation dose-dependent manner as a consequence of three responses. Initially, enhanced degradation of existing proteins occurred which resulted in an increased intracellular peptide pool. Subsequently, enhanced translation due to activation of the mammalian target of rapamycin pathway resulted in increased peptide production, antigen presentation, as well as cytotoxic T lymphocyte recognition of irradiated cells. In addition, novel proteins were made in response to gamma-irradiation, resulting in new peptides presented by MHC class I molecules, which were recognized by cytotoxic T cells. We show that immunotherapy is successful in eradicating a murine colon adenocarcinoma only when preceded by radiotherapy of the tumor tissue. Our findings indicate that directed radiotherapy can improve the efficacy of tumor immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“irradiation can also increase tumor antigenicity through enriching the pool of antigenic peptides”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Reits et al., 2006
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In silico prediction of protein-protein interactions in human macrophages
Souiai, O., Guerfali, F., Ben Miled, S., Brun, C., & Benkahla, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-157 · Cited by 10,803
Significance analysis of microarrays applied to the ionizing radiation response
Tusher, V. G., Tibshirani, R., & Chu, G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091062498 · Cited by 10,568
Phenotypic Analysis of Antigen-Specific T Lymphocytes
Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., & Davis, M. M. (1996) · Science · doi:10.1126/science.274.5284.94 · Cited by 3,544 · cited 1×
“folding the HLA-A1 heavy chain with peptides CGI-51(206–215), MSH6(469–478), and F-box protein Fbl7(335–362) and human β2m as described (51).”
BackgroundDNA double-strand breaks: signaling, repair and the cancer connection
Khanna, K. K., & Jackson, S. P. (2001) · Nature Genetics · doi:10.1038/85798 · Cited by 2,455
Rapid degradation of a large fraction of newly synthesized proteins by proteasomes
Schubert, U., Antón, L. C., Gibbs, J., Norbury, C. C., Yewdell, J. W., & Bennink, J. R. (2000) · Nature · doi:10.1038/35008096 · Cited by 1,536
Error-Tolerant Identification of Peptides in Sequence Databases by Peptide Sequence Tags
Mann, M., & Wilm, M. (1994) · Analytical Chemistry · doi:10.1021/ac00096a002 · Cited by 1,468
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated
Demaria, S., Ng, B., Devitt, M. L., Babb, J. S., Kawashima, N., Liebes, L., & Formenti, S. C. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.09.012 · Cited by 1,388
Fingar, D. C., & Blenis, J. (2004) · Oncogene · doi:10.1038/sj.onc.1207542 · Cited by 1,247
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
Lee, P. P., Yee, C., Savage, P. A., Fong, L., Brockstedt, D., Weber, J. S., Johnson, D., Swetter, S., Thompson, J., Greenberg, P. D., et al. (1999) · Nature Medicine · doi:10.1038/9525 · Cited by 1,113
Lugade, A. A., Moran, J. P., Gerber, S. A., Rose, R. C., Frelinger, J. G., & Lord, E. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7516 · Cited by 966 · cited 3×
“This is probably not due only to up-regulation of MHC class I expression because mTOR activation will have more general eff ects on protein expression including up-regulation of Fas, ICAM-1 (38), and interferon expression (33, 34).”
Background
Research works printed but not linked: 5
- 2000, Oncology (Huntingt), 14, 741
- 1988, Nippon Igaku Hoshasen Gakkai Zasshi., 48, 1572
- 2000, Anticancer Res., 20, 3375
- 2002, Cancer Res., 62, 1462
- 1991, Cancer Res., 51, 3657
Cited by
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809697 · Cited by 2,798
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
The immune contexture in cancer prognosis and treatment
Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263
Towards a systems understanding of MHC class I and MHC class II antigen presentation
Neefjes, J., Jongsma, M. L. M., Paul, P., & Bakke, O. (2011) · Nature Reviews Immunology · doi:10.1038/nri3084 · Cited by 2,044
Self-citationImmunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
Bruni, D., Angell, H. K., & Galon, J. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0285-7 · Cited by 1,586
Rudin, C. M., Brambilla, E., Faivre-Finn, C., & Sage, J. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00235-0 · Cited by 1,570
Immunogenic cell stress and death
Kroemer, G., Galassi, C., Zitvogel, L., & Galluzzi, L. (2022) · Nature Immunology · doi:10.1038/s41590-022-01132-2 · Cited by 1,353
Cancer despite immunosurveillance: immunoselection and immunosubversion
Zitvogel, L., Tesniere, A., & Kroemer, G. (2006) · Nature reviews. Immunology · doi:10.1038/nri1936 · Cited by 1,324
Lee, Y., Auh, S. L., Wang, Y., Burnette, B., Wang, Y., Meng, Y., Beckett, M., Sharma, R., Chin, R., Tu, T., et al. (2009) · Blood · doi:10.1182/blood-2009-02-206870 · Cited by 1,324
Shaverdian, N., Lisberg, A. E., Bornazyan, K., Veruttipong, D., Goldman, J. W., Formenti, S. C., Garon, E. B., & Lee, P. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30380-7 · Cited by 1,091
Radiotherapy and immunotherapy: a beneficial liaison?
Weichselbaum, R. R., Liang, H., Deng, L., & Fu, Y.-X. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.211 · Cited by 1,070
Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
Formenti, S. C., & Demaria, S. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs629 · Cited by 1,053
Systemic effects of local radiotherapy
Formenti, S. C., & Demaria, S. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70082-8 · Cited by 1,021
Combination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944
Cancer nanomedicine for combination cancer immunotherapy
Nam, J., Son, S., Park, K. S., Zou, W., Shea, L. D., & Moon, J. J. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0108-1 · Cited by 940
Phagocytosis checkpoints as new targets for cancer immunotherapy
Feng, M., Jiang, W., Kim, B. Y. S., Zhang, C. C., Fu, Y.-X., & Weissman, I. L. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0183-z · Cited by 911
Sharabi, A. B., Lim, M., DeWeese, T. L., & Drake, C. G. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00007-8 · Cited by 899
Inflammatory microenvironment remodelling by tumour cells after radiotherapy
McLaughlin, M., Patin, E. C., Pedersen, M., Wilkins, A., Dillon, M. T., Melcher, A. A., & Harrington, K. J. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0246-1 · Cited by 883
Burnette, B. C., Liang, H., Lee, Y., Chlewicki, L., Khodarev, N. N., Weichselbaum, R. R., Fu, Y.-X., & Auh, S. L. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2820 · Cited by 878
Zitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.014 · Cited by 870
Clinical significance of tumor-infiltrating lymphocytes in breast cancer
Stanton, S. E., & Disis, M. L. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0165-6 · Cited by 828
Role of Local Radiation Therapy in Cancer Immunotherapy
Demaria, S., Golden, E. B., & Formenti, S. C. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2756 · Cited by 779
Radiation-Induced CXCL16 Release by Breast Cancer Cells Attracts Effector T Cells
Matsumura, S., Wang, B., Kawashima, N., Braunstein, S., Badura, M., Cameron, T. O., Babb, J. S., Schneider, R. J., Formenti, S. C., Dustin, M. L., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.5.3099 · Cited by 711
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Challenges and Opportunities for Pancreatic Cancer Immunotherapy
Bear, A. S., Vonderheide, R. H., & O'Hara, M. H. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.004 · Cited by 674
Radiotherapy combined with immunotherapy: the dawn of cancer treatment
Zhang, Z., Liu, X., Chen, D., & Yu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01102-y · Cited by 670
Immune parameters affecting the efficacy of chemotherapeutic regimens
Zitvogel, L., Kepp, O., & Kroemer, G. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.223 · Cited by 669
Sharabi, A. B., Nirschl, C. J., Kochel, C. M., Nirschl, T. R., Francica, B. J., Velarde, E., Deweese, T. L., & Drake, C. G. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0196 · Cited by 658
Combination strategies to maximize the benefits of cancer immunotherapy
Zhu, S., Zhang, T., Zheng, L., Liu, H., Song, W., Liu, D., Li, Z., & Pan, C.-X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01164-5 · Cited by 654
Cytokines and their relationship to the symptoms and outcome of cancer
Seruga, B., Zhang, H., Bernstein, L. J., & Tannock, I. F. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2507 · Cited by 652
DNA Damage and Repair Biomarkers of Immunotherapy Response
Mouw, K. W., Goldberg, M. S., Konstantinopoulos, P. A., & D'Andrea, A. D. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0226 · Cited by 645
(2013) · Advances in Cancer Research · doi:10.1016/b978-0-12-407190-2.00007-1 · Cited by 594
Reynders, K., Illidge, T., Siva, S., Chang, J. Y., & De Ruysscher, D. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.03.011 · Cited by 574
The anticancer immune response: indispensable for therapeutic success?
Zitvogel, L., Apetoh, L., Ghiringhelli, F., André, F., Tesniere, A., & Kroemer, G. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35180 · Cited by 573
Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
Patel, S. A., & Minn, A. J. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.007 · Cited by 573
Adusumilli, P. S., Cherkassky, L., Villena-Vargas, J., Colovos, C., Servais, E., Plotkin, J., Jones, D. R., & Sadelain, M. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3010162 · Cited by 572
NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
Wang, W. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00368 · Cited by 567
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
Emens, L. A., Ascierto, P. A., Darcy, P. K., Demaria, S., Eggermont, A. M. M., Redmond, W. L., Seliger, B., & Marincola, F. M. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.035 · Cited by 566
Immunoproteasomes Preserve Protein Homeostasis upon Interferon-Induced Oxidative Stress
Seifert, U., Bialy, L. P., Ebstein, F., Bech-Otschir, D., Voigt, A., Schröter, F., Prozorovski, T., Lange, N., Steffen, J., Rieger, M., et al. (2010) · Cell · doi:10.1016/j.cell.2010.07.036 · Cited by 551
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
Zappasodi, R., Merghoub, T., & Wolchok, J. D. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.005 · Cited by 525
Immunobiology of Allogeneic Hematopoietic Stem Cell Transplantation
Welniak, L. A., Blazar, B. R., & Murphy, W. J. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141606 · Cited by 520
TGFβ is a master regulator of radiation therapy-induced antitumor immunity
Vanpouille-Box, C., Diamond, J. M., Pilones, K. A., Zavadil, J., Babb, J. S., Formenti, S. C., Barcellos-Hoff, M. H., & Demaria, S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3511 · Cited by 514
Radiotherapy combination opportunities leveraging immunity for the next oncology practice
Herrera, F. G., Bourhis, J., & Coukos, G. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21358 · Cited by 509
Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect
Rodríguez-Ruiz, M. E., Vanpouille-Box, C., Melero, I., Formenti, S. C., & Demaria, S. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.06.001 · Cited by 497
Filatenkov, A., Baker, J., Mueller, A. M. S., Kenkel, J., Ahn, G.-O., Dutt, S., Zhang, N., Kohrt, H., Jensen, K., Dejbakhsh-Jones, S., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2824 · Cited by 474
Radiotherapy and Immunogenic Cell Death
Golden, E. B., & Apetoh, L. (2015) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2014.07.005 · Cited by 463
Abscopal effect of radiotherapy combined with immune checkpoint inhibitors
Liu, Y., Dong, Y., Kong, L., Shi, F., Zhu, H., & Yu, J. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0647-8 · Cited by 447
Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation
Gupta, A., Probst, H. C., Vuong, V., Landshammer, A., Muth, S., Yagita, H., Schwendener, R., Pruschy, M., Knuth, A., & van den Broek, M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200563 · Cited by 446
Radiotherapy and the Tumor Stroma: The Importance of Dose and Fractionation
Hellevik, T., & Martinez-Zubiaurre, I. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00001 · Cited by 442
Dong, Z.-Y., Zhang, J.-T., Liu, S.-Y., Su, J., Zhang, C., Xie, Z., Zhou, Q., Tu, H.-Y., Xu, C.-R., Yan, L.-X., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1356145 · Cited by 440
Gameiro, S. R., Jammeh, M. L., Wattenberg, M. M., Tsang, K. Y., Ferrone, S., & Hodge, J. W. (2014) · Oncotarget · doi:10.18632/oncotarget.1719 · Cited by 415
Self-citationLiu, Y., Ramot, Y., Torrelo, A., Paller, A. S., Si, N., Babay, S., Kim, P. W., Sheikh, A., Lee, C. R., Chen, Y., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.33368 · Cited by 406
Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?
Bernstein, M. B., Krishnan, S., Hodge, J. W., & Chang, J. Y. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.30 · Cited by 399
Self-citationRecurrent glioma clinical trial, CheckMate-143: the game is not over yet
Filley, A. C., Henriquez, M., & Dey, M. (2017) · Oncotarget · doi:10.18632/oncotarget.21586 · Cited by 386
Grimaldi, A. M., Simeone, E., Giannarelli, D., Muto, P., Falivene, S., Borzillo, V., Giugliano, F. M., Sandomenico, F., Petrillo, A., Curvietto, M., et al. (2014) · OncoImmunology · doi:10.4161/onci.28780 · Cited by 379
Molecular Mechanisms of Radiation-Induced Cancer Cell Death: A Primer
Sia, J., Szmyd, R., Hau, E., & Gee, H. E. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00041 · Cited by 378
Intratumoral immunotherapy: using the tumor as the remedy
Marabelle, A., Tselikas, L., de Baere, T., & Houot, R. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx683 · Cited by 375
Wang, Y., Deng, W., Li, N., Neri, S., Sharma, A., Jiang, W., & Lin, S. H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00185 · Cited by 374
Improving radiotherapy in cancer treatment: Promises and challenges
Chen, H. H. W., & Kuo, M. T. (2017) · Oncotarget · doi:10.18632/oncotarget.18409 · Cited by 372
Current clinical trials testing the combination of immunotherapy with radiotherapy
Kang, J., Demaria, S., & Formenti, S. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0156-7 · Cited by 371
Influence of HLA-C Expression Level on HIV Control
Apps, R., Qi, Y., Carlson, J. M., Chen, H., Gao, X., Thomas, R., Yuki, Y., Del Prete, G. Q., Goulder, P., Brumme, Z. L., et al. (2013) · Science · doi:10.1126/science.1232685 · Cited by 371
Dovedi, S. J., Cheadle, E. J., Popple, A. L., Poon, E., Morrow, M., Stewart, R., Yusko, E. C., Sanders, C. M., Vignali, M., Emerson, R. O., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1673 · Cited by 370
Mechanisms regulating T-cell infiltration and activity in solid tumors
Lanitis, E., Dangaj, D., Irving, M., & Coukos, G. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx238 · Cited by 369
Emerging evidence for adapting radiotherapy to immunotherapy
Galluzzi, L., Aryankalayil, M. J., Coleman, C. N., & Formenti, S. C. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00782-x · Cited by 368
Radiotherapy: Changing the Game in Immunotherapy
Demaria, S., Coleman, C. N., & Formenti, S. C. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.05.002 · Cited by 363
Induced sensitization of tumor stroma leads to eradication of established cancer by T cells
Zhang, B., Bowerman, N. A., Salama, J. K., Schmidt, H., Spiotto, M. T., Schietinger, A., Yu, P., Fu, Y.-X., Weichselbaum, R. R., Rowley, D. A., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062056 · Cited by 359
Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs
Diamond, J. M., Vanpouille-Box, C., Spada, S., Rudqvist, N.-P., Chapman, J. R., Ueberheide, B. M., Pilones, K. A., Sarfraz, Y., Formenti, S. C., & Demaria, S. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0581 · Cited by 358
Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?
Muranski, P., Boni, A., Wrzesinski, C., Citrin, D. E., Rosenberg, S. A., Childs, R., & Restifo, N. P. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0666 · Cited by 358
Jochems, C., & Schlom, J. (2011) · Experimental Biology and Medicine · doi:10.1258/ebm.2011.011007 · Cited by 353
Self-citationCellular Senescence Is Immunogenic and Promotes Antitumor Immunity
Marin, I., Boix, O., Garcia-Garijo, A., Sirois, I., Caballe, A., Zarzuela, E., Ruano, I., Attolini, C. S.-O., Prats, N., López-Domínguez, J. A., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0523 · Cited by 346
Altorki, N. K., McGraw, T. E., Borczuk, A. C., Saxena, A., Port, J. L., Stiles, B. M., Lee, B. E., Sanfilippo, N. J., Scheff, R. J., Pua, B. B., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00149-2 · Cited by 342
Marciscano, A. E., Ghasemzadeh, A., Nirschl, T. R., Theodros, D., Kochel, C. M., Francica, B. J., Muroyama, Y., Anders, R. A., Sharabi, A. B., Velarde, E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3427 · Cited by 335
Radiation as an immunological adjuvant: current evidence on dose and fractionation
Demaria, S., & Formenti, S. C. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00153 · Cited by 332
Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy
Young, K. H., Baird, J. R., Savage, T., Cottam, B., Friedman, D., Bambina, S., Messenheimer, D. J., Fox, B., Newell, P., Bahjat, K. S., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0157164 · Cited by 325
Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?
Tang, C., Wang, X., Soh, H., Seyedin, S., Cortez, M. A., Krishnan, S., Massarelli, E., Hong, D., Naing, A., Diab, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0069 · Cited by 322
Tang, C., Welsh, J. W., de Groot, P., Massarelli, E., Chang, J. Y., Hess, K. R., Basu, S., Curran, M. A., Cabanillas, M. E., Subbiah, V., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1432 · Cited by 321
Time to abandon single-site irradiation for inducing abscopal effects
Brooks, E. D., & Chang, J. Y. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0119-7 · Cited by 313
Yu, W.-D., Sun, G., Li, J., Xu, J., & Wang, X. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.02.048 · Cited by 308
Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy
Ciardiello, D., Vitiello, P. P., Cardone, C., Martini, G., Troiani, T., Martinelli, E., & Ciardiello, F. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.04.003 · Cited by 304
Phase 1 Study of Stereotactic Body Radiotherapy and Interleukin-2—Tumor and Immunological Responses
Seung, S. K., Curti, B. D., Crittenden, M., Walker, E., Coffey, T., Siebert, J. C., Miller, W., Payne, R., Glenn, L., Bageac, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003649 · Cited by 303
Demaria, S., Guha, C., Schoenfeld, J., Morris, Z., Monjazeb, A., Sikora, A., Crittenden, M., Shiao, S., Khleif, S., Gupta, S., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002038 · Cited by 301
The role of dendritic cells in cancer and anti-tumor immunity
Marciscano, A. E., & Anandasabapathy, N. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101481 · Cited by 298
Wan, S., Pestka, S., Jubin, R. G., Lyu, Y. L., Tsai, Y.-C., & Liu, L. F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032542 · Cited by 295
Safety of combining radiotherapy with immune-checkpoint inhibition
Hwang, W. L., Pike, L. R. G., Royce, T. J., Mahal, B. A., & Loeffler, J. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0046-7 · Cited by 295
A review of glioblastoma immunotherapy
Medikonda, R., Dunn, G., Rahman, M., Fecci, P., & Lim, M. (2021) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03448-1 · Cited by 295
Mechanisms of immune evasion in breast cancer
Bates, J. P., Derakhshandeh, R., Jones, L., & Webb, T. J. (2018) · BMC Cancer · doi:10.1186/s12885-018-4441-3 · Cited by 291
Radiation and immunotherapy: a synergistic combination
Kalbasi, A., June, C. H., Haas, N., & Vapiwala, N. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69219 · Cited by 284
Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
Apetoh, L., Ladoire, S., Coukos, G., & Ghiringhelli, F. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv209 · Cited by 280
Giaccone, G., Bazhenova, L. A., Nemunaitis, J., Tan, M., Juhász, E., Ramlau, R., van den Heuvel, M. M., Lal, R., Kloecker, G. H., Eaton, K. D., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.07.035 · Cited by 279
Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend
Locy, H., de Mey, S., de Mey, W., De Ridder, M., Thielemans, K., & Maenhout, S. K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02909 · Cited by 279
A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion
Dersh, D., Hollý, J., & Yewdell, J. W. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-0390-6 · Cited by 278
Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system
Lhuillier, C., Rudqvist, N.-P., Elemento, O., Formenti, S. C., & Demaria, S. (2019) · Genome Medicine · doi:10.1186/s13073-019-0653-7 · Cited by 276
Verbrugge, I., Hagekyriakou, J., Sharp, L. L., Galli, M., West, A., McLaughlin, N. M., Duret, H., Yagita, H., Johnstone, R. W., Smyth, M. J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0210 · Cited by 275
The Effect of Radiation on the Immune Response to Cancers
Park, B., Yee, C., & Lee, K.-M. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15010927 · Cited by 272
Antitumour dendritic cell vaccination in a priming and boosting approach
Harari, A., Graciotti, M., Bassani-Sternberg, M., & Kandalaft, L. E. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0074-8 · Cited by 271
Non-canonical NF-κB Antagonizes STING Sensor-Mediated DNA Sensing in Radiotherapy
Hou, Y., Liang, H., Rao, E., Zheng, W., Huang, X., Deng, L., Zhang, Y., Yu, X., Xu, M., Mauceri, H., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.07.008 · Cited by 265
Wang, X., Schoenhals, J. E., Li, A., Valdecanas, D. R., Ye, H., Zang, F., Tang, C., Tang, M., Liu, C.-G., Liu, X., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-15-3142 · Cited by 261
Metadata
- Authors
- Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., Griekspoor, A., Mesman, E., Verreck, F. A., Spits, H., Schlom, J., van Veelen, P., & Neefjes, J. J.
- Affiliations
- The Netherlands Cancer Institute (NL)
- 2Laboratory of Tumor Immunology and Biology
- National Institutes of Health (US)
- 4Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, and Centre for Medical Systems Biology, 2333 2A Leiden, Netherlands
- Leiden University Medical Center (NL)
- ORCID
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2006-04-24
- Volume
- 203
- Issue
- 5
- Pages
- 1259-1271
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC3212727
- OpenAlex
- W2127733313
- Cited by
- 1,737
- References
- 53
- Citations by year
- 2026: 88 · 2025: 116 · 2024: 119 · 2023: 128 · 2022: 149 · 2021: 174 · 2020: 154 · 2019: 118 · 2018: 112 · 2017: 113 · 2016: 78 · 2015: 71 · 2014: 67 · 2013: 62 · 2012: 41
- FWCI
- 10.85
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- radiotherapy, gamma irradiation, MHC class I expression, antigen presentation, protein degradation, mTOR signaling, translation (biology), cytotoxic T lymphocytes, cancer immunotherapy, colon adenocarcinoma
- MeSH terms
- Adenocarcinoma, Animals, Colonic Neoplasms, Dose-Response Relationship, Radiation, Gamma Rays, Humans, Immunotherapy, Mice, Transgenic, Peptides, Protein Kinases, Radiotherapy, T-Lymphocytes, Cytotoxic, Protein Biosynthesis, HLA-A2 Antigen, Gene Expression Regulation, Neoplastic, Antigen Presentation, Mice, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.